Likhitha C’s Post

🛑Brexin Tablets: Detailed Information 🛑Brand Company Brexin is manufactured by Chiesi Farmaceutici, an Italian pharmaceutical company. 🛑 Formulas Brexin contains piroxicam-beta-cyclodextrin as the active ingredient. The combination enhances the solubility and absorption of piroxicam, potentially leading to a quicker onset of action. 🛑 Mechanism of Action (MOA) Piroxicam, the active component, is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the enzyme cyclooxygenase (COX). This enzyme is involved in the synthesis of prostaglandins, which are mediators of inflammation and pain. By blocking COX, piroxicam reduces the production of prostaglandins, thereby decreasing inflammation and alleviating pain. 🛑Uses Brexin is primarily used for the treatment of: - Osteoarthritis - Rheumatoid arthritis - Ankylosing spondylitis - Acute musculoskeletal disorders (e.g., sprains, strains, and injuries) 🛑 Side Effects Common side effects of Brexin may include: 1. Gastrointestinal issues (nausea, vomiting, stomach pain, indigestion, ulcers) 2.Headache 3.Dizziness 4.Skin reactions (rash, itching) 5.Edema (swelling due to fluid retention) Serious side effects can include: 1.Gastrointestinal bleeding or perforation 2.Kidney damage 3.Cardiovascular events (heart attack, stroke) 4.Severe allergic reactions (anaphylaxis, angioedema) 🛑Precautions 1.Gastrointestinal Risk: Use with caution in patients with a history of gastrointestinal ulcers, bleeding, or perforation. 2.Cardiovascular Risk: Patients with cardiovascular disease or risk factors should use Brexin with caution. 3.Kidney and Liver Function: Regular monitoring may be required for patients with impaired kidney or liver function. 4.Allergic Reactions: Avoid use in patients with known hypersensitivity to piroxicam or other NSAIDs. 5.Pregnancy and Breastfeeding: Brexin should be avoided during pregnancy, especially in the third trimester, and during breastfeeding unless specifically advised by a healthcare professional. 6.Interactions: Brexin may interact with other medications such as anticoagulants, other NSAIDs, corticosteroids, and certain antihypertensive drugs. Always inform your healthcare provider about all medications you are taking. .

🚀 Revolutionizing Administration: From INJECTIONS to ORAL DELIVERY 💊 The case study of Rybelsus. An example of a biobetter drug that has transitioned from an injectable form to an oral formulation is Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood sugar levels by enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying. 💉 Initially, semaglutide was available only as an injectable formulation (Ozempic), to manage blood sugar levels and promote weight loss in patients with type 2 diabetes, with a weekly administration. 💊 The development of the oral formulation, Rybelsus, marketed in 2019, represents a significant advancement, providing a non-injectable option for patients taken once daily. Benefits of the Oral Formulation: 1. Enhanced Glycemic Control: Oral semaglutide provides effective glycemic control, reducing HbA1c levels significantly more than some other oral glucose-lowering therapies. 2. Weight Reduction: Studies indicate that Rybelsus aids in weight reduction, a crucial benefit for many patients with type 2 diabetes. 3. Cardiovascular Benefits: Oral semaglutide demonstrated a favorable cardiovascular safety profile, comparable to injectable semaglutide. 4. Convenient Administration: The oral formulation allows for easier administration, improving patient adherence and comfort by eliminating the need for injections. Development and Approval: ▪ Clinical Trials: The development of Rybelsus involved demonstrating that the oral formulation of semaglutide could be absorbed effectively in the gastrointestinal tract and provide consistent blood levels to achieve the desired therapeutic effects. Trials compared the efficacy and safety of oral semaglutide with the injectable form and other diabetes medications. ▪ Regulatory Approval: Rybelsus was approved by the FDA based on positive clinical trial results, providing a new and innovative option for diabetes management. The transition from injectable Ozempic to oral Rybelsus illustrates how changing the delivery method of a medication can significantly enhance patient convenience and adherence while maintaining therapeutic efficacy. This shift exemplifies the “BioBetter” concept by offering a more patient-friendly option without compromising the effectiveness of the treatment. 🌱💡At Plantibodies, we are following this path by addressing other gastrointestinal diseases with innovative oral formulations. Hopefully, soon GI-tract diseases will no longer need to be treated with injections, making therapies more accessible and comfortable for patients and lowering the burden on the health-care system. To gain comprehensive insights into the scientific advantages of Rybelsus over Ozempic, read the instructive publication of Filip K. Knop, Andrea Battisti, and Tina Vilsbøll here: https://lnkd.in/gvMfQ5_g #mAbs #Oraldelivery #Biotechnology #MolecularFarming #Biologics #Lifesciences

𝑰𝒏𝒏𝒐𝒗𝒂𝒕𝒊𝒐𝒏𝒔 𝒊𝒏 𝑫𝒓𝒖𝒈 𝑫𝒆𝒍𝒊𝒗𝒆𝒓𝒚 𝑺𝒚𝒔𝒕𝒆𝒎𝒔 Introduction: Drug delivery systems (DDS) are cutting-edge technologies that are used to distribute pharmaceutical substances. By increasing patient compliance, efficiency, and precision, DDS can improve treatment efficacy, lessen adverse effects, and solve administration issues that have long existed. Key Innovations: 𝟭. 𝗡𝗮𝗻𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆-𝗕𝗮𝘀𝗲𝗱 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗦𝘆𝘀𝘁𝗲𝗺𝘀: - Nanoparticles: Engineered carriers known as nanoparticles improve medication absorption, lower toxicity, and enable targeted therapy—particularly in cancer treatment—by supplying chemotherapy straight to tumour cells. - Liposomes: Pharmaceuticals are delivered via liposomes, which are spherical vesicles with a lipid bilayer that shield pharmaceuticals from breaking down. Anticancer medications, vaccinations, and antibacterial treatments have all been effectively delivered using liposomes. 𝟮. 𝗕𝗶𝗼𝗱𝗲𝗴𝗿𝗮𝗱𝗮𝗯𝗹𝗲 𝗣𝗼𝗹𝘆𝗺𝗲𝗿𝘀: - Drug delivery systems that use polymers break down over time to provide regulated drug release. This is particularly useful in sustained-release formulations, which minimize the need for frequent dosing. 𝟯. 𝗧𝗿𝗮𝗻𝘀𝗱𝗲𝗿𝗺𝗮𝗹 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗦𝘆𝘀𝘁𝗲𝗺𝘀: - Patches: Transdermal patches offer a non-invasive substitute for oral or injectable drug delivery systems by enabling drug absorption through the skin. These are frequently used for hormone therapy, nicotine replacement, and pain management. The goals of innovations in this field are to increase drug stability, patch adherence, and delivery rate. - Microneedles: Tiny needles penetrate skin's outer layer to deliver drugs without pain, used for vaccines, insulin, and other therapies where traditional injection methods are less desirable. 𝟰. 𝗜𝗺𝗽𝗹𝗮𝗻𝘁𝗮𝗯𝗹𝗲 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗦𝘆𝘀𝘁𝗲𝗺𝘀: - Implants: Long-term medication release devices with programmable release rates and invasive refilling are helpful for chronic disorders including cancer and cardiovascular diseases when they are inserted beneath the skin or other bodily tissues. 𝟱. 𝗢𝗿𝗮𝗹 𝗧𝗵𝗶𝗻 𝗙𝗶𝗹𝗺𝘀 (𝗢𝗧𝗙𝘀): - Dissolvable films called OTFs are used to administer medications via the oral mucosa. This improves patient compliance and has a rapid beginning of action, especially for older and juvenile patients. 𝟲. 𝗦𝗺𝗮𝗿𝘁 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 - Responsive Systems: Drug release systems are precisely delivered to the proper location and time within the body by being regulated by certain stimuli such as temperature changes, pH shifts, or the presence of enzymes. - Wearable Devices: Developments in wearable technology allow devices to monitor physiological characteristics, allowing insulin pumps and other devices that give drugs depending on real-time glucose levels.

THE LONGEVITY (of) DRUGS - True therapeutic testing takes time and tons of testimonial. A fantastic example of not counting your chickens before they hatch…. News out: MRHA Yellow Warning reporting mandate for effects seen with Antibiotics of the same class as Ciprofloxacin can cause serious, permanent toxicity… Think of an ECG/EKG there’s an initial blip of an idea, a little dip as people quieten down till initial trials results come out, that huge upward spike of hype (and investor interest) followed by and then an equally big down turn as reality kicks an and the next big thing kicks in, then eventually, if it’s a hugely beneficial long term therapy with no late toxic effects that make the whole profession feel very sheepish about what they’ve been prescribing for years, then you get the final long uplift efficacy that doesn’t fade until the next big idea comes along. The but all too often we only discover the true effect after thousands or millions of real world doses are given and patterns evolve showing long term toxicity that outweighs the lives or limbs (or dollars) saved. Remember the results of our drug trials are only properly over after two or three decades. Humbling. Big example today is the news finally out (thank goodness) on Fluoroquinolone antibiotics. No one ever likes giving Cipro’ and the like. Intuitive physicians often feel it’s a horrid thing to give patients despite the guidance from on high that it was okay for us to prescribe. It does cause profound retrospection when you hear this news and what harm we have inadvertently caused by this drug. Not that it’s the first or last time this will happen. An intriguing side effect of testing therapeutics for the diseases of ageing are the absolute necessity for buying markers that look for long-term detrimental damage or positive signs that might indicate that the drug being tested will improve long-term health and prevent diseases of aging. Drugs tested for issues like for instance an infection only look for short-term benefit normally like the infection going away and observations of side-effects come second. Perhaps every drug we develop should also look at biomarkers of long-term health such as the ones developed for treating or preventing the disease of aging, that might actually give us foresight into what the eventual three decade results on our bodies will be. #healthcare #trials #pharma #longevity Jordan Shlain, MD Eric Verdin https://lnkd.in/e2j9R3z8

A brand new weight reduction drug could see patients lose double the quantity of fat they’d shift on popular medications like Ozempic, early trial data has shown. Obese patients taking the once-weekly injection lost roughly 19 percent of their body weight, on average, after five and a half months of the treatment. In comparison, various trials have shown that semaglutide — the medication in Wegovy and Ozempic — ends in around 10 percent reduction in body weight after six months. Further, those with pre-diabetes on the brand new drug were all found to be in remission by the top of the trial. The study data, unveiled by Swiss pharma giant Roche Thursday, shows that the speed of uncomfortable side effects is comparable to that of other currently available injections. The trial from Roche showed participants on the drug lost 18.8 percent of their body weight over 24 weeks on average Roche’s share price jumped 4 percent on the news of the brand new drug. Shown above over the past five days Side effects included mild to moderate gastrointestinal effects comparable to nausea and vomiting. The drug, called CT-388, was tested in a phase 1 trial, designed to ascertain whether medications are protected for human use. The study involved 31 obese adults with no underlying conditions including type 2 diabetes. A separate trial is planned to check the drug in diabetics. At week 24, results showed that 45 percent of participants had lost greater than 20 percent of their body weight. All the participants had lost at the least five percent of their weight. Ozempic and Wegovy work by mimicking high levels of naturally occurring hormones that regulate blood sugar and suppress appetite. Roche’s drug acts similarly to Mounjaro and Zepbound, made by pharma firm Eli Lilly. It comprises the drug tirzepatide which, unlike semaglutide, acts on not one but two appetite-suppressing hormones. These are Glucagon-like peptide-1 (GLP-1) and the hormone Glucose-dependent insulinotropic polypeptide (GIP) — which each trigger feelings of fullness and suppress appetite. Studies on Mounjaro and Zepbound suggest patients can expect to lose about 20 percent of their body weight after 36 weeks on the once weekly medications. Dr Levi Garraway, Roche’s chief medical officer, said: ‘We are more than happy to see the numerous and clinically meaningful weight reduction in people treated with CT-388. ‘The results are highly encouraging for further development of CT-388 for each obesity and sort 2 diabetes and underscore its potential to turn into a best-in-class therapy with durable weight reduction and glucose control.’ The drug has an extended option to go before it reaches the approval stage, with several further trials needed to prove efficacy. A price for the medication also has not been revealed, but Ozempic retails at upwards of $900 per 30 days. The development comes as pharmaceutical firms race to money in on the load loss

Drug-Induced Thrombocytopenic Purpura (DITP): A Potentially Serious Adverse Reaction Thrombocytopenic purpura is a condition characterized by low platelet counts leading to bruising, bleeding, and purpura (small red or purple spots on the skin). When caused by a medication, it is termed Drug-Induced Thrombocytopenic Purpura (DITP), and it can be life-threatening if not promptly recognized and managed. Here’s what you need to know: 🔹 Mechanism of DITP DITP occurs when drugs induce an immune-mediated response that targets and destroys platelets or disrupts their production. The rapid drop in platelets (often within a few days of exposure to the drug) can lead to bleeding risks and complications. 🔹 Common Culprit Drugs A variety of drugs have been associated with DITP, including: Antibiotics: Penicillins, cephalosporins, vancomycin, and sulfonamides. Anticonvulsants: Valproic acid, carbamazepine. Antiplatelet & Anticoagulants: Heparin (HIT - Heparin-Induced Thrombocytopenia), ticlopidine. NSAIDs: Ibuprofen, naproxen. Cardiovascular Drugs: Quinidine, abciximab. Anticancer Agents: Chemotherapeutics that affect bone marrow function can also cause DITP. 🔹 Symptoms & Clinical Presentation Patients may present with bruising (ecchymosis), petechiae, nosebleeds (epistaxis), or gum bleeding. Severe cases can result in gastrointestinal bleeding, hematuria, or intracranial hemorrhage. 🔹 Diagnosis & Management Diagnosis: DITP diagnosis requires a thorough medication history, ruling out other causes of thrombocytopenia (e.g., infections, autoimmune conditions), and often identifying a temporal relationship between drug exposure and symptom onset. Management: The primary treatment is to discontinue the causative drug immediately. Platelet counts usually recover within 5-10 days after stopping the drug. In some cases, supportive care such as platelet transfusions or corticosteroids may be required. 🔹 Preventive Measures & Monitoring Monitoring Platelet Counts: Regular monitoring of platelet counts in patients starting new medications known to cause DITP can facilitate early detection. Patient Education: Educate patients on recognizing early signs of thrombocytopenia (e.g., easy bruising, unusual bleeding) to ensure prompt medical evaluation. By recognizing potential drug-associated risks for DITP, healthcare professionals can better manage and prevent this serious adverse reaction, enhancing patient safety. #DITP #Thrombocytopenia #DrugSafety #AdverseReactions #PatientSafety #Pharmacovigilance #Healthcare

Concerns of misuse of diabetic drugs for weight loss purposes in India  https://lnkd.in/dQPvUKTR #healthtech #innovation #Vaccines #pharmaceutals #manufacturing #HealthcareInnovation #Funding #biologics

🔍 Drug-Induced Pancreatitis & Antidiabetic Medications – What You Need to Know Acute pancreatitis is a known risk associated with some antidiabetic medications. While these drugs play a crucial role in glycemic control for patients with diabetes, it's essential to be aware of their potential to trigger drug-induced pancreatitis. 1️⃣ Classes of Antidiabetic Drugs Associated with Pancreatitis GLP-1 Receptor Agonists (e.g., Exenatide, Liraglutide) These medications mimic glucagon-like peptide-1 (GLP-1) to enhance insulin secretion and have been associated with reports of pancreatitis. Patients on GLP-1 receptor agonists should be monitored for abdominal pain, nausea, and vomiting. DPP-4 Inhibitors (e.g., Sitagliptin, Saxagliptin) Dipeptidyl peptidase-4 inhibitors work by increasing incretin levels and enhancing insulin production. Cases of pancreatitis have been reported, though the incidence remains relatively low. It's crucial to assess patients for risk factors before initiating therapy. SGLT-2 Inhibitors (e.g., Canagliflozin, Dapagliflozin) While the primary focus with SGLT-2 inhibitors has been on their effects on cardiovascular and renal outcomes, there have been occasional reports of pancreatitis. Monitoring for early symptoms is advisable. 2️⃣ Mechanisms & Risk Factors The exact mechanisms by which these drugs may induce pancreatitis are not fully understood but may involve altered enzyme secretion, inflammation, and changes in pancreatic tissue. Risk Factors for developing pancreatitis with antidiabetic drugs include: Alcohol use Gallstones Obesity High triglycerides Previous history of pancreatitis 3️⃣ Clinical Presentation Patients may present with sudden-onset abdominal pain, which can radiate to the back, along with nausea, vomiting, and elevated pancreatic enzymes (amylase, lipase). Symptoms typically improve upon discontinuation of the medication and supportive care for pancreatitis. 4️⃣ Management & Monitoring Assess patient history before starting antidiabetic medications to identify those at higher risk for pancreatitis. Educate patients to recognize the symptoms of pancreatitis and encourage immediate medical attention if they occur. In the event of pancreatitis, discontinue the suspected medication and provide appropriate supportive care. 5️⃣ Benefit-Risk Balance It's crucial to weigh the benefits of glycemic control with the potential risks of pancreatitis, particularly for patients with other risk factors. Regular re-evaluation of the patient’s treatment plan is essential to ensure that the benefit-risk profile remains favorable. 📣 Understanding the potential link between antidiabetic medications and pancreatitis allows for informed clinical decisions, optimal patient care, and timely intervention. Have you experienced challenges in managing patients on antidiabetic drugs? Share your insights! 👇 #Pharmacovigilance #DrugSafety #DiabetesManagement #Pancreatitis #PatientSafety #Endocrinology #RiskManagement #Healthcare

A brief overview of commonly used type 2 diabetes drugs: 1. Metformin: It's a first-line oral medication for type 2 diabetes. Metformin works by reducing glucose production in the liver, increasing insulin sensitivity in tissues, and decreasing glucose absorption in the intestines. It's usually well-tolerated and has few side effects, with gastrointestinal issues being the most common. 2. Gliclazide: This is a sulfonylurea medication used to treat type 2 diabetes. Gliclazide stimulates insulin release from the pancreas, helping to lower blood sugar levels. It's taken orally and can cause hypoglycemia (low blood sugar) as a side effect, especially if not taken correctly. 3. GLP-1 (Glucagon-like peptide-1) agonists: These are injectable medications that mimic the action of the natural hormone GLP-1. They work by stimulating insulin secretion, suppressing glucagon secretion (which lowers blood sugar), slowing gastric emptying, and promoting satiety. GLP-1 agonists can lead to weight loss and have cardiovascular benefits. Common side effects include nausea and vomiting. 4. SGLT-2 (Sodium-glucose co-transporter-2) inhibitors: These drugs block the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and lowering blood sugar levels. They also have additional benefits such as reducing blood pressure and promoting weight loss. Common side effects include urinary tract infections and genital yeast infections.

GLP-1 Drug Shortages and Potential Health Risks for Non-Diabetic Patients 🚨 We are currently facing a shortage of GLP-1 receptor agonist medications like Ozempic (Novo Nordisk), Trulicity (Eli Lilly and Company), Victoza (Novo Nordisk), and Mounjaro (Eli Lilly and Company). While these drugs are essential for managing type 2 diabetes, their off-label use for weight loss among non-diabetic patients is contributing to supply shortages and posing potential health risks. What are the potential risks for non-diabetic users❓ 👁️ Eye-Related Issues: There have been reports of eye problems, such as diabetic retinopathy complications, in some patients using GLP-1 drugs, particularly when used improperly or without the need to manage diabetes. This can lead to vision changes, eye pain, or even more severe eye conditions. Non-diabetic patients should be particularly cautious, as the benefit-risk profile of using these drugs without diabetes is not well understood. 🤢 Gastrointestinal Side Effects: Many non-diabetic patients experience significant gastrointestinal discomfort, including nausea, vomiting, diarrhea, and constipation. These symptoms can range from mild to severe and often lead to discontinuation of the medication. ⚠️ Pancreatitis: GLP-1 drugs have been associated with an increased risk of pancreatitis, a serious condition that causes inflammation of the pancreas. Symptoms include severe abdominal pain, nausea, and vomiting, which can be life-threatening if not treated promptly. 🩺 Gallbladder Problems: There is also a risk of developing gallbladder issues, such as gallstones or cholecystitis (inflammation of the gallbladder), which can cause severe pain and require surgical intervention. 🛑 Thyroid Tumors: Some GLP-1 receptor agonists have been linked to an increased risk of thyroid tumors in animal studies. Although this risk has not been conclusively shown in humans, caution is advised, especially for those with a personal or family history of thyroid cancer. What can we do❓ It’s critical for healthcare providers to assess the necessity of GLP-1 drugs for non-diabetic patients and to discuss potential side effects and alternative weight management strategies. Pharmaceutical companies and policymakers must prioritize access for individuals with diabetes who rely on these medications to prevent serious complications, including cardiovascular events and kidney damage. Let’s ensure these powerful medications are used responsibly and that those who need them most can access them. #BTHT #Healthcare #GLP1 #Diabetes #Pharma #NovoNordisk #EliLilly #Ozempic Sources: - American Diabetes Association - FDA (Food and Drug Administration) - Novo Nordisk - Eli Lilly